Comparison
NMN vs Rapamycin
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Rapamycin
mTOR inhibitor approved for immunosuppression after organ transplant. Studied off-label for longevity at low intermittent doses.
| Field | NMN | Rapamycin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 5–10mg |
| Half-life | — | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●○○○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 600 | 36000 |
The comparison in plain English
Auto-generated from dataNMN and Rapamycin are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Rapamycin mTOR inhibitor approved for immunosuppression after organ transplant.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Rapamycin (evidence A, safety 2/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Rapamycin if
Rapamycin is the better fit when your goal aligns with its mechanism (Selective inhibitor of mTORC1 (mechanistic target of rapamycin complex 1), reducing protein synthesis and inducing autophagy) and the dose range (5–10mg) suits your protocol. Half-life is —h.